This report, titled “Analysis of Group Financial Statements,” analyzes the consolidated financial performance of Beximco Pharmaceuticals Limited and its subsidiaries—Nuvista Pharma Limited and Synovia Pharma PLC—for the fiscal years 2022–2023. The study focuses on evaluating the group’s financial health, operational performance, and the impact of subsidiary acquisitions using key financial indicators.

The report applies a descriptive research methodology based on secondary data from audited annual financial statements and follows relevant IFRS standards such as IFRS 10, IAS 1, IAS 7, and IAS 8. Financial performance is assessed through profitability, liquidity, solvency, and efficiency ratios, along with pre- and post-acquisition comparisons.

Findings show that after the acquisitions, total assets and equity increased by 10.47% and 9.86% respectively, indicating successful consolidation and balance sheet growth. Although total comprehensive income declined slightly by 1.39%, this was attributed to initial integration and restructuring costs rather than long-term weakness. Liquidity improved significantly, with cash and cash equivalents increasing by 21%.

The group demonstrated strong profitability with a net profit margin of 11.52%, sound liquidity with a current ratio of 1.57, low financial risk reflected by a debt-to-equity ratio of 0.17, and moderate efficiency shown by an inventory turnover ratio of 1.80. Revenue grew by 13.26%, largely driven by strategic acquisitions, particularly contributions from Nuvista and Synovia.

The report concludes that Beximco Pharmaceuticals is financially stable and well-positioned for long-term growth. However, it recommends improving subsidiary integration, increasing R&D investment, enhancing inventory efficiency, and diversifying therapeutic segments to strengthen competitiveness and sustain future growth.